Shares of Medpace Holdings Inc (NASDAQ:MEDP) have earned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $73.75.
MEDP has been the topic of several recent analyst reports. Credit Suisse Group lifted their price target on Medpace from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 30th. SunTrust Banks lifted their price objective on Medpace to $85.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Robert W. Baird lifted their price objective on Medpace from $57.00 to $62.00 and gave the stock a “neutral” rating in a report on Tuesday, April 30th. Zacks Investment Research raised Medpace from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a report on Wednesday, July 10th. Finally, BidaskClub raised Medpace from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd.
Shares of NASDAQ MEDP opened at $78.91 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.66 and a debt-to-equity ratio of 0.07. The business’s 50 day moving average is $70.97 and its two-hundred day moving average is $61.82. The company has a market cap of $2.87 billion, a P/E ratio of 30.47, a P/E/G ratio of 2.20 and a beta of 1.57. Medpace has a 12 month low of $45.88 and a 12 month high of $82.39.
Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 29th. The company reported $0.81 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.18. The company had revenue of $214.10 million for the quarter, compared to the consensus estimate of $200.99 million. Medpace had a return on equity of 17.65% and a net margin of 11.28%. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 EPS. Sell-side analysts expect that Medpace will post 2.91 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in Medpace by 9.8% in the second quarter. BlackRock Inc. now owns 4,538,605 shares of the company’s stock worth $296,914,000 after purchasing an additional 406,428 shares in the last quarter. Colony Group LLC acquired a new position in Medpace in the second quarter worth $2,036,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Medpace by 53.9% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock worth $40,000 after purchasing an additional 212 shares in the last quarter. United Services Automobile Association boosted its stake in Medpace by 2.4% in the second quarter. United Services Automobile Association now owns 6,639 shares of the company’s stock worth $434,000 after purchasing an additional 155 shares in the last quarter. Finally, Waddell & Reed Financial Inc. acquired a new position in Medpace in the second quarter worth $2,891,000. 81.44% of the stock is currently owned by institutional investors.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
See Also: What does a hold rating mean?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.